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Clinical Outcomes After Drug-Eluting Stents Versus Coronary
Artery Bypass Surgery in High Surgical Risk Patients With
Left Main or Three-Vessel Coronary Artery Disease
Tonga Nfor, MD, MSPH, Kambiz Shetabi, MD, Wael Hassan, MD, Quinta Nfor, MSN, Jayant Khitha, MD,
Anjan Gupta, MD, Tanvir Bajwa, MD, Suhail Allaqaband, MD
Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of
Medicine and Public Health, Milwaukee, WI

Purpose	Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass
graft surgery (CABG) in patients with unprotected left main or three-vessel coronary artery disease
(LM-3VD) have excluded patients at high surgical risk. We compared clinical outcomes after PCI with
drug-eluting stents to CABG in high surgical risk patients with LM-3VD.
Methods

 atients with symptomatic LM-3VD who had Society of Thoracic Surgeons (STS)-predicted operative
P
mortality > 5% and were undergoing either PCI with drug-eluting stents or CABG at a tertiary care
center from January 2009 to December 2010 were enrolled in this nonrandomized prospective study.

Results		Mean STS score was 14.5 ± 5.8% for PCI (n=83) versus 13.6 ± 7.1% for CABG (n=187) (P=0.31). After
mean follow-up of 37 months, incidence of the composite primary endpoint (death, myocardial infarction
or stroke) was 42.2% for PCI and 39.6% for CABG (P=0.69, hazard ratio 1.3, 95% confidence interval
0.5–2.8). There were no differences in the individual components of the primary endpoint between
PCI and CABG. Repeat revascularization was 30.1% for PCI versus 9.6% for CABG (P=0.001). Major
adverse cardiac and cerebrovascular event rates were similar between PCI and CABG, 50.6% versus
42.2%, respectively (P=0.23). Patients in the PCI group were less likely than those in the CABG group to
be discharged to a nursing home (12.1% vs. 47.1%, P<0.001) and had shorter hospital stays (5.6 ± 5.7
days vs. 15.1 ± 10.6 days, P<0.001).
Conclusions	
The composite rate of death, myocardial infarction or stroke is similar for PCI and CABG in patients
with symptomatic LM-3VD who have STS-predicted operative mortality > 5%.
Keywords
high risk, three-vessel disease, left main, Heart Team, stenting, coronary artery bypass
		grafting

Left main or three-vessel coronary artery disease (LM3VD) occurs in 27% of men and 8% of women older
than 30 years who undergo coronary angiography
for suspected coronary artery disease.1,2 Without
revascularization, the prognosis is dismal, with 3-year
mortality of 24% for three-vessel disease without
left main disease3 and 30–50% when left main
disease is present.4,5 Coronary artery bypass graft
surgery (CABG) is the traditional gold standard for
revascularization of LM-3VD.6-10 Over the past decade,

outcomes of percutaneous coronary intervention (PCI)
in complex coronary artery disease have improved due
to advances in stent design and other interventional
equipment, effectiveness of pharmacotherapy and
experience of operators.11,12 Recent randomized
controlled trials have shown that overall major adverse
cardiac and cerebrovascular events (MACCE) are
lower with CABG than PCI in patients revascularized
for unprotected LM-3VD.13-18 However, the outcomes
of CABG and PCI were similar in patients who have
focal disease with SYNTAX score ≤ 22.18,19
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Due to the more invasive nature and higher shortterm morbidity of CABG, PCI has been empirically
considered a good alternative to CABG in patients
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who are deemed a high surgical risk. In clinical
practice, surgical risk is defined by different criteria
including age,20,21 general frailty22,23 and surgical risk
scores.24,25 The latest guidelines for PCI recommend
consideration of PCI over CABG in patients with
LM-3VD who have favorable coronary anatomy for
PCI when Society for Thoracic Surgeons (STS) score
predicts operative mortality as > 5%.7 However, this
threshold is arbitrary and not based on published data
because high surgical risk patients were excluded from
major studies comparing PCI to CABG. The aim of
this study was to compare clinical outcomes after
PCI with drug-eluting stents versus CABG in patients
with unprotected LM-3VD who have STS-predicted
operative mortality > 5%.

METHODS

Design
This was a nonrandomized prospective study comparing
clinical outcomes between high surgical risk patients
who underwent PCI versus those who underwent
CABG for symptomatic LM-3VD. Local institutional
review board approval and signed informed consent
from the subjects were obtained for the study.
Patients and Procedures
Consecutive patients who underwent PCI with drugeluting stents or CABG for symptomatic unprotected
LM-3VD at a single tertiary care center from January
2009 to December 2010 were included in the study
if they had a baseline STS-predicted operative
mortality > 5%. Documentation of ischemia based on
symptoms of classic angina, a positive noninvasive
test, newly decreased left ventricular ejection
fraction or acute coronary syndrome was required.
Patients were excluded from the study if they had
previously undergone CABG or had a concomitant
cardiac pathology that needed treatment at the time
of revascularization (e.g. significant valve disease).
Patients also were excluded if they had an allergy to
aspirin or clopidogrel.
Left main revascularization was performed for
angiographic stenosis > 50% or minimal luminal area ≤
6 mm2 as determined by intravascular ultrasound. Other
epicardial arteries were revascularized for angiographic
stenosis > 70%, minimal luminal area by ultrasound < 4
mm2 on proximal segments or fractional flow reserve <
96
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0.8. The choice of revascularization method was at the
discretion of the treating physicians and their patients,
usually with collaboration from our institution’s
multidisciplinary Heart Team. Periprocedural therapies
and maintenance treatments were provided according
to standard clinical guidelines.
Data Collection
A previously tested and validated data collection
questionnaire was used to extract data from patients’
electronic medical records. Baseline sociodemographic
and clinical comorbidities as well as indications for
revascularization were recorded. Information on
equipment used, medications given and grafts used were
obtained from procedural reports and case documents.
Angiograms were reviewed by two independent
cardiologists, and SYNTAX scores were calculated
using the online SYNTAX Score Calculator®, Version
2.1 (www.syntaxscore.com).26 Surgical risk scores
were calculated for all patients using the online logistic
EuroSCORE calculator (www.euroscore.org/calc.
html)27 as well as the STS Risk Calculator (riskcalc.
sts.org/STSWebRiskCalc273/).28
Endpoints
Endpoints were identified by reviewing data from
patients’ medical records. Patients who had no
follow-up records were called for a phone interview
to inquire about cardiac events. The primary endpoint
was a composite of death from any cause, myocardial
infarction or stroke, whichever occurred first.
Individual secondary endpoints were myocardial
infarction, stroke, death from any cause and ischemiadriven repeat revascularization. MACCE constituted
a composite secondary endpoint comprising the
four individual secondary endpoints. Myocardial
infarction was defined as a rise and fall in troponin
associated with ischemic symptoms, new ischemic
changes on electrocardiogram, new regional wall
motion abnormalities or loss of viable myocardium on
imaging. Stroke was defined as a new focal neurological
deficit lasting > 24 hours or radiological evidence
of acute cerebral infarction or hemorrhage. Repeat
revascularization was defined as any subsequent PCI or
CABG after the index procedure that was performed for
definite angina, worsening cardiomyopathy, abnormal
noninvasive study or acute coronary syndromes. Outof-hospital deaths were identified through the National
Original Research

RESULTS

Figure 1. Study population flow chart. 3VD, three-vessel coronary artery disease; CABG, coronary artery
bypass graft surgery; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons.

Death Index. Follow-up time was counted from the
date of index revascularization.
Statistical Analyses
Summary descriptive statistics for continuous variables
were expressed as means (± standard deviation),
and univariate comparisons were made between PCI
and CABG groups using the Mann-Whitney U test.
Categorical variables were reported as percentages and
compared using Fisher’s exact test. Treatment selection
bias was overcome by using propensity-matched
analysis. A propensity score was calculated for each
patient using multivariate binary logistic regression,
which was calculated as the probability of undergoing
PCI (rather than CABG) as predicted by baseline
characteristics, namely age, sex, race, cardiac risk
factors, comorbidities, acuity of clinical presentation,
presence of left main disease and SYNTAX score.
Cumulative event rates were compared using KaplanMeier analysis and the log-rank test. Hazard ratios
with 95% confidence intervals (CI) were calculated by
multivariate Cox regression adjusting for propensity
score, STS score, SYNTAX score and left main disease.
We assessed the model for overfitting by tracking the
trend in the adjusted R2-values and deterioration in
the P-values of regression coefficients. Prespecified
stratified analyses were performed to determine
subgroup differences. All P-values were two-sided.
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Of 362 patients revascularized for LM-3VD with a
baseline STS score > 5%, 92 patients were excluded
(Figure 1). The mean age in our final study sample
(n=270) was 77 ± 9 years, and 44% were women.
Patients ≥ 80 years old made up 41.9% of the study.
There was high prevalence of comorbidities in both
study groups (Table 1). The high-risk profile of the
study sample is illustrated by the mean STS score of
13.9 ± 6.8%. There were 39.6% of patients with an STS
score ≥ 15, which is considered extreme risk. Although
there was no difference in the mean STS score between
PCI and CABG, more patients revascularized with PCI
fell in this extreme risk category (63.9% vs. 28.9%,
P<0.001). There was no significant difference in
SYNTAX score and number of lesions between the
PCI and CABG groups, but left main disease was more
common in the PCI group while the average number
of arteries revascularized was greater in the CABG
group. Other baseline characteristics were similarly
distributed between the two groups.
All patients were followed for at least 24 months, with
a total mean follow-up of 37 months (range: 24–49
months). There was complete verification of all primary
endpoints. Figure 2 shows Kaplan-Meier curves for
survival free of the primary endpoint (i.e. composite
death, myocardial infarction or stroke). Although there
was no significant difference in the incidence of the
primary endpoint between both groups, there seemed
to be a biphasic trend for lower (but not statistically
significant) incidence in the PCI group during the
first 9 months and then lower in the CABG group
after 9 months. The 1-month incidence of the primary
endpoint was 14.5% for PCI versus 19.3% for CABG
(P=0.39). The incidence of the primary endpoint at
the end of the 3.1-year study period was 42.2% for
PCI versus 39.6% for CABG (P=0.69, hazard ratio:
1.3, 95% CI: 0.5–2.8). We performed further analysis
to compare the primary endpoint between PCI and
CABG within subgroups of patients defined by the
presence of predictors of adverse outcomes at baseline
(Figure 3). There was no difference in the primary
endpoint between PCI and CABG among patients who
had left main disease or three-vessel disease. There
also was no significant interaction between method of
revascularization and either STS score, age, diabetes,
previous cardiothoracic surgery, left ventricular
ejection fraction or SYNTAX score.
www.aurora.org/jpcrr
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Table 1. Baseline patient characteristics
Variable
Age, years

PCI (n=83)

CABG (n=187)

P

76.5 ± 9

77 ± 9.6

0.71

Women

41.0

44.9

0.55

White

78.3

85.6

0.16

Diabetes mellitus

50.6

42.2

0.21

Smoker

51.8

50.3

0.89

Chronic lung disease

46.3

36.8

0.17

Renal failure*

23.2

24.7

0.78

45.8

26.2

0.001

60.2

20.3

<0.001

18.1

23.5

0.32

STEMI

9.6

8.6

0.82

Non-STEMI/unstable angina

33.7

30.5

0.67

Stable coronary disease

56.6

60.9

0.51

STS score

14.5 ± 5.8

13.6 ± 7.1

0.31

EuroSCORE

21.8 ± 14

19.8 ± 15

0.24

SYNTAX score

37.0 ± 12

40.0 ± 15

0.12

62.6

39.6

<0.001

73.5

84.0

0.06

2.5 ± 0.7

2.9 ± 0.3

0.001

4.5 ± 2

4.8 ± 1.1

0.35

Aspirin

92.8

90.3

0.18

P2Y12 inhibitor

95.2

14.4

<0.001

Beta blocker

81.9

75.4

0.31

Statin

85.5

75.4

0.08

ACEI/ARB

54.2

25.7

0.001

Prior PCI
Prior cardiothoracic surgery

†

LVEF ≤ 30%
Clinical presentation

Left main disease
Three-vessel disease
Number of arteries

§

Number of lesions
Discharge medications

Internal mammary artery used

92.5

Number of grafts per patient

2.7 ± 0.8

Off-pump surgery

4.3

Stent type
Everolimus-eluting

59.0

Zotarolimus-eluting

21.7

Sirolimus-eluting

18.1

Paclitaxel-eluting

1.2

Values are percentage or mean ± standard deviation.
*Creatinine > 2 mg/dL.
†
Noncoronary cardiothoracic surgery like valves, structural heart disease, thoracic aorta, etc.
§
Grouped by main arteries –– right coronary, left main, left anterior descending and left circumflex.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft
surgery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation
myocardial infarction; STS, Society of Thoracic Surgeons.
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Table 2. Three-year outcomes of high surgical risk patients with left main or three-vessel coronary artery
disease after revascularization
PCI
(n=83)

CABG
(n=187)

P*

Adjusted hazard ratio†
(95% CI)

Death, MI or stroke

42.2%

39.6%

0.69

1.3 (0.5–2.8)

Death

36.1%

32.1%

0.57

1.5 (0.4–3.0)

Acute MI

4.9%

4.4%

0.96

1.1 (0.6–1.9)

Stroke

4.9%

8.2%

0.44

0.7 (0.2–1.5)

Repeat revascularization

30.1%

9.6%

0.001

3.1 (1.6–9.1)

MACCE

50.6%

42.2%

0.23

1.7 (0.7–7.2)

*Calculated using Fisher’s exact test.
†Hazard ratio compares PCI vs. CABG adjusted for propensity score, baseline comorbidities, Society of Thoracic Surgeons
score, SYNTAX score and left main disease.
CABG, coronary artery bypass graft surgery; CI, confidence interval; MACCE, major adverse cardiac and cerebrovascular
event (death, MI, stroke or repeat revascularization); MI, myocardial infarction; PCI, percutaneous coronary intervention.

Comparisons of secondary endpoints are shown
in Table 2. Over the study period the rates of the
individual endpoints of death, myocardial infarction
and stroke were similar between PCI and CABG. The
30-day mortality was 12.1% for PCI versus 14.4%
for CABG (P=0.70). Because our data sources were
unreliable in correctly identifying the cause of death,
we could not accurately specify cardiac mortality. The
incidence of stroke was lower for PCI than CABG
during the first year of follow-up only; the difference
was not significant thereafter. Stroke rates were 1.2%
for PCI versus 7.5% for CABG at 30 days (P=0.038),
and 2.4% versus 8.0%, respectively, at 1 year (P=0.08).
Unfortunately, the databases we accessed did not have
follow-up tracking of stroke or residual disability out to
3 years. Repeat revascularization was the only clinical
event with a significant difference. The rate of repeat
revascularization was three times greater for PCI than
CABG. All repeat revascularizations were performed
by PCI. Putting all four individual endpoints together,
the rate of MACCE was similar between PCI and
CABG over 3.1 years.
We used length of stay as a surrogate for resource
utilization during the index hospitalization. Both
median length of stay in the intensive care unit and total
hospital length of stay were significantly shorter for
PCI than CABG (Figure 4). The mean intensive care
unit stay was 2.1 ± 3.6 days for PCI versus 7.4 ± 8.8
days for CABG, a mean difference of 5.3 days (95% CI:
3.8–6.8, P<0.001). The mean total length of stay during
Original Research

Figure 2. Kaplan-Meier curves for survival free of the

primary endpoint (death, myocardial infarction or stroke)
in high surgical risk patients treated with percutaneous
coronary intervention (PCI) or coronary artery bypass
graft surgery (CABG).

index hospitalization was 5.6 ± 5.7 days for PCI versus
15.1 ± 10.6 days for CABG, a mean difference of 9.5
days (95% CI: 7.6–11.5, P<0.001). We also compared
discharge destinations between the PCI and CABG
groups. In the PCI group 85.5% were discharged home
and 12.1% went to a specialized nursing/rehabilitation
facility versus 41.7% going home and 47.1% going to a
www.aurora.org/jpcrr
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Figure 3. Multivariate

Cox regression analysis within subgroups of
patients comparing combined outcome of death,
myocardial infarction or
stroke in high surgical
risk patients revascularized with percutaneous
coronary intervention
(PCI) or coronary artery
bypass graft surgery
(CABG). *Event rates
are expressed as number of events/number of
patients at risk (percentage). †P-value for interaction. ‡No patients in
subgroup, hence P-value calculated from other
two subgroups. LVEF,
left ventricular ejection
fraction; STS, Society of
Thoracic Surgeons.

specialized nursing/rehabilitation facility after CABG
(P<0.0001). Two patients (2.4%) from the PCI group
died in the hospital, whereas 21 patients (11.2%) from
the CABG group died in the hospital (P=0.017).

DISCUSSION

We performed a nonrandomized prospective study
to compare the outcomes of PCI using drug-eluting
stents and CABG in patients with unprotected LM3VD who had baseline STS-predicted operative
mortality > 5%. Over a mean follow-up period of
3.1 years the composite primary endpoint of death,
myocardial infarction or stroke occurred in 42.2% of
PCI patients and 39.6% of CABG patients (P=0.69).
There was no difference in the primary endpoint
among subgroups of patients with left main disease
and those with three-vessel disease. The respective
individual endpoints were similar between PCI and
CABG. Repeat revascularization was more than three
times more likely in PCI than CABG but did not lead
to a higher rate of MACCE. Length of intensive care
unit stay and total duration of index hospitalization
was significantly longer for CABG than PCI. Patients
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treated with CABG were nearly four times more likely
to be discharged to a specialized nursing facility than
those treated with PCI.
This is the first study to directly compare PCI and
CABG in high surgical risk patients. In the SYNTAX
trial, the mean EuroSCORE-predicted mortality among
randomized patients was 3.8 ± 2.6%.14 Even in the PCI
registry arm, where patients were enrolled due to high
surgical risk, the mean EuroSCORE was only 5.8 ±
3.1%.14 In the LE MANS registry of patients with left
main disease treated by PCI, the mean EuroSCORE was
6.0 ± 2.8%, and the observed mortality and MACCE
rates were 13.9% and 25.4%, respectively, after a mean
follow-up of 3.8 years.29 The mean EuroSCORE in our
study was 21.8%. Advanced age is one of the most
important surgical risk factors. In a nonrandomized
study of 249 patients ≥ 80 years old that compared
PCI to CABG in patients with unprotected left main
disease, there was no difference in rates of MACCE
between PCI (43.3%) and CABG (35.2%) after a
mean follow-up of about 2 years (hazard ratio: 1.11,
95% CI: 0.59–2.0).30 About 20% of these patients had

Original Research

concomitant three-vessel disease. Although this study
included patients based on only one component of
surgical risk, the findings were similar to our study.
High surgical risk patients with LM-3VD present a
clinical dilemma. The decision of how to revascularize
these patients is even more difficult when SYNTAX
score is high. The importance of managing these
patients using a comprehensive Heart Team approach
cannot be overemphasized.7,8,31 The mortality rate is
high in patients with multiple comorbidities who are
not revascularized; however, our study shows high
mortality even after either surgical or percutaneous
revascularization. This finding underscores the
importance of taking into account the overall prognosis
when considering revascularization in high-risk
patients. Our subgroup analysis showed no difference
between PCI and CABG irrespective of SYNTAX or
STS score category, but the subgroup numbers are
too small to draw conclusions. Modifications have
been proposed to reduce operative mortality and
morbidity in these high-risk patients. Off-pump CABG
may reduce operative complications and mortality
compared to on-pump CABG, but may not be suitable
for complex coronary anatomies.32 Hybrid coronary
revascularization is another alternative to traditional
CABG or PCI alone in high-risk patients. Surgery is
done to graft an internal mammary artery to the left
anterior descending artery, then PCI is performed on
other coronary arteries.33 Small nonrandomized studies
comparing hybrid revascularization to traditional
CABG have shown similar short-term results, but
long-term outcomes are unknown.33,34 An appropriate
discussion to have is when revascularization should
be attempted in high-risk patients and how highrisk revascularization compares to optimal medical
treatment alone. A third treatment arm of optimal
medical therapy would have been informative;
unfortunately, such a group with sufficient follow-up
data could not be identified for this study.
There are some limitations to our study. Our definition
of high surgical risk as STS-predicted mortality > 5%
may not be acceptable to everyone. However, this is the
value used to quantify high surgical risk in the 2011 PCI
guidelines.7 The STS score28 and EuroSCORE27 are the
two most commonly used and best validated tools to
quantify surgical risk in patients undergoing open heart
Original Research

Figure 4. Total hospital and intensive care unit (ICU)

stays in high surgical risk patients revascularized with
percutaneous coronary intervention (PCI) or coronary
artery bypass graft surgery (CABG) for left main or
three-vessel coronary artery disease.

surgery. Both scores have good predictive accuracy for
operative mortality, but STS score may perform slightly
better than EuroSCORE.35 Newer scoring methods
for PCI that add clinical variables to angiographic
characteristics, like the “clinical SYNTAX score” and
the “SYNTAX II score,” have shown better accuracy
than the angiographic SYNTAX score used in this
study in predicting adverse events.36,37 Unfortunately,
unlike the angiographic SYNTAX score, these newer
scores have not been tested in a study on CABG
patients and have not made it into routine clinical
practice. In our study it was not entirely clear for all
patients how decisions were made to undergo one
method of revascularization versus the other. A formal
surgical consult was documented in only 45 of the 83
patients treated by PCI. Counting CABG patients, this
means 232 (86%) out of all 270 patients were officially
assessed by the Heart Team comprised of a surgeon
and cardiologist. We believe this study reflects real-life
practice in which the cardiologist and patient together
decide to skip the surgical consult when there is a
strong preference for PCI by the patient. However, it
is important to reemphasize here the necessity of a
proper Heart Team consultation.7,8,31 Third, our study
demonstrated greater upfront resource use and shortterm morbidity (based on length of stay and discharge
to specialized nursing facility) after CABG than PCI
www.aurora.org/jpcrr
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in high surgical risk patients with LM-3VD. We,
however, did not integrate actual cost data and cannot
conclude that any initial cost savings will translate into
long-term cost benefit given the greater need for repeat
revascularization in the PCI group. Lastly, our study
represents the experience of a single center and was
not randomized. Our sample size may also be too small
to draw definite conclusions.

CONCLUSIONS

In patients with unprotected left main or three-vessel
coronary artery disease who have an STS-predicted
operative mortality > 5%, the combined rate of death,
myocardial infarction or stroke is similar in those
revascularized by percutaneous coronary intervention
with drug-eluting stents or coronary artery bypass
graft surgery. PCI was associated with a higher rate of
repeat revascularization than CABG, but this did not
translate into a higher rate of major adverse cardiac
and cerebrovascular events. Compared to patients
who underwent CABG, those who underwent PCI had
shorter intensive care unit and hospital stays and were
also more likely to be discharged home as opposed to
a specialized nursing facility. PCI may be the preferred
method of myocardial revascularization over CABG
in high surgical risk patients with left main or threevessel coronary artery disease due to its lower early
morbidity but similar long-term clinical outcomes.

Patient-Friendly Recap
• As clinical techniques and technology advance,
standard treatment recommendations must be
continuously reviewed and updated.
• Patients with coronary artery disease in whom
bypass surgery is deemed high risk may be
better served by a less invasive revascularization
procedure, called PCI, that uses drug-eluting
stents to improve blood flow.
• The authors compared this type of PCI to surgery
in high-risk patients and found similar success
rates between the two.
• They also noted that patients who undergo
PCI are able to leave the hospital sooner but
require a future procedure more often than their
counterparts who undergo surgery.
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